Search

everythinglearnresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

Lichen Sclerosus causes itching, pain, and potential complications in the genital area.

Patients with skin diseases rated psychological effects as most impactful, needing a treatment approach that addresses both mind and body.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

The document's conclusion cannot be provided because the content is not accessible.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Oral baricitinib is effective and safe for treating alopecia areata.

Certain hair and scalp features can predict the severity of alopecia areata.

A new treatment plan helps manage folliculitis decalvans effectively.

Trichoscopy helps better understand and manage alopecia areata, improving patient outcomes.

The Spanish HSS-29 scale effectively measures changes in life quality due to female-pattern hair loss.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Most patients with autoimmune blistering diseases experienced some hair loss, which may be underreported and linked to disease severity.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Scoring systems help doctors assess and treat skin diseases effectively.

Current tools inadequately measure quality of life in children with alopecia areata, needing better instruments.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.